Follitropin Alfa (Merck)

Financial results of Q2 2023 Net sales decrease organically by −1.1% to € 5.3 billion EBITDA pre down organically by −7.0% to € 1.6 billion Healthcare business sector increases net sales and earnings Weaker market environment in Life Science and Electronics Negative foreign exchange impact stronger than in Q1 2023 Updated forecast for fiscal 2023 Net sales: Organic development between −2% and +2 % Net sales excluding Covid-19 business: Organic growth of +1% to +5% EBITDA pre: Organic decline of −9% to −3% Foreign exchange impact on both net sales and EBITDA pre: −6% to −3% Darmstadt, Germany, August 3, 2023 – In the second quarter of 2023, Merck KGaA, Darmstadt, Germany, leveraged its diversified portfolio with three business sectors to navigate a challenging market environment. While net sales of Life Science and Electronics declined in softer markets, Healthcare delivered organic sales growth of 11.9%. Overall, Group net sales decreased by −4.8% to € 5,302 million compared to the same quarter of the previous year. The strong growth of the Healthcare business sector largely offset the decline in Life Science and Electronics, resulting in an organic development of Group sales of −1.1%. Despite the strong earnings growth of Healthcare, Group EBITDA pre declined by −12.8% (organically −7.0%) to € 1,553 million. This was caused primarily by decreased sales volumes and the proportionately lower share of higher-margin products. Negative foreign exchange effects put further pressure on both net sales and EBITDA pre. Against this backdrop, the company is updating its forecast for fiscal 2023. The company now expects an organic development of Group net sales of between −2% and +2% (previously +1% to +4%) along with an organic decline in EBITDA pre by −9% to −3% (previously: −5% to 0%). Excluding the Covid-19 business, Group sales are expected to grow organically by +1% to +5% (previously: +4% to +7%). Both net sales and EBITDA pre are likely to be impacted by negative foreign exchange effects of −6% to −3% (previously: −5% to −2%). “For us, 2023 remains a transition year,” said Belén Garijo, Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany. “In the second quarter, our Healthcare business once again proved to be a growth driver. We are building on the strengths of our diversified business model. We remain confident of our mid-term growth ambition and in delivering € 25 billion in sales by 2025.” Headwinds from foreign exchange effects pick up in Q2 2023 Sales in the second quarter of 2023 decreased organically by −1.1%. Foreign exchange effects, especially from the U.S. dollar and the Chinese renminbi, had an adverse impact of −3.7% on sales. By contrast, in the first quarter of 2023, foreign exchange effects still contributed positively to sales growth by 0.8%. EBITDA pre declined organically by −7.0% in the second quarter of 2023. The impact of foreign exchange on Group EBITDA pre was −5.7%. The EBITDA pre margin was 29.3%. Earnings per share pre were € 2.20. Weaker market environment in Life Science and Electronics weighs on business performance in the first half of 2023 In the first half of 2023, the Group generated net sales of € 10,595 million, reflecting a decline of −1.6% (organic: −0.2%) compared to the same period of the previous year. While net sales of the Healthcare business sector grew organically by 8.8% in the first six months of 2023, Life Science (−4.2%) and Electronics (−6.7%) reported organic sales decreases. The main reasons were the significant decline in Covid-19-related demand and the weaker market environment in both Semiconductor Solutions and Display Solutions. Organically, Group EBITDA pre decreased by −4.5% to € 3,140 million in the first half of 2023. Earnings per share pre were € 4.57. Life Science: Significant decrease in Covid-19-related demand drives organic decline in net sales and earnings In the second quarter of 2023, the Life Science business sector reported net sales of € 2,354 million, a decrease of −11.1% compared with the same quarter of the previous year. Organically, sales declined by −8.7%. Foreign exchange effects had a negative impact of −2.4% on sales. The Process Solutions and Life Science Services business units recorded organic sales declines of −11.8% and −30.5%, respectively. The main reasons were the significantly lower Covid-19-related demand and a considerable slow-down in the core business of Process Solutions due to destocking by key customers. Organically, EBITDA pre of Life Science decreased by −26.1% to € 712 million. Lower sales volumes were a significant factor for this decline, as was the comparatively lower share of higher-margin products in sales, partly driven by lower Covid-19-related sales. Foreign exchange had a negative impact of −3.3% on earnings. The EBITDA pre margin of Life Science was 30.2%. Healthcare: New products remain growth drivers, complemented by the positive development of the established product portfolio In the second quarter of 2023, the Healthcare business sector increased net sales by 6.5% (organically: 11.9%) to € 2,049 million, amid a negative foreign exchange impact of −5.4%. The key growth drivers were the new launches, namely of the immuno-oncology drug Bavencio, which grew organically by 26.8%, as well as Mavenclad for the treatment of relapsing multiple sclerosis, which generated organic growth of 28.1%. The established product portfolio also contributed positively to sales growth. Organically, net sales of the oncology drug Erbitux increased by 10.2% in the second quarter of 2023. The Fertility franchise generated organic sales growth of 24.7% compared with the same quarter of the previous year. Ongoing supply difficulties of a competitor had a favorable impact on net sales of the fertility products. In addition, the market for fertility treatments in China continued its recovery after the Covid-19-related lockdowns ended. In the second quarter of 2023, EBITDA pre of the Healthcare business sector amounted to € 704 million. Organic earnings growth of 30.4% was partly offset by negative foreign exchange effects of −13.9%. The EBITDA pre margin of Healthcare was 34.3%. Electronics: Second quarter impacted by weaker market environment in Semiconductor Solutions and Display Solutions The Electronics business sector recorded a −9.7% decline in net sales to € 899 million in the second quarter of 2023. Organically, sales decreased by −6.3% amid a foreign exchange effect of −3.8%. The Semiconductor Solutions business unit reported an organic sales decline of −4.7%. The robust project business in Delivery Systems & Services (DS&S) largely offset the decline in Semiconductor Materials in what was, as expected, a weaker market. A recovery in the Semiconductor Materials business is delayed further. Market consensus now assumes a stabilization in the second half of the year at a continued low level. Continued weak pricing and the comparatively lower share of higher-margin products in liquid crystals were the main reasons for the organic sales decline of −10.9% in the Display Solutions business unit. EBITDA pre of Electronics declined organically by −5.2% to € 262 million. Foreign exchange had a negative impact on EBITDA pre of −4.9%. The EBITDA pre margin was 29.1%. Updated forecast for fiscal 2023 Merck KGaA, Darmstadt, Germany, is updating its forecast for fiscal 2023. The reasons for this are, in particular, the persistently high inventory levels of our Life Science customers, the further delayed recovery of the market for semiconductor materials, an increased cost level due to inflation and an even stronger negative foreign exchange impact. The company once again confirms its mid-term objective of delivering sales of € 25 billion by 2025. For fiscal 2023, the forecast for the Group is as follows: Organic sales development: −2% to +2%, totaling € 20.5 billion to € 21.9 billion Organic sales growth excluding Covid-19 business: +1% to +5% Organic decline of EBITDA pre: −9% to −3%, totaling € 5.8 billion to € 6.4 billion Negative foreign exchange effects on sales and EBITDA pre: −6% to −3% EPS pre: € 8.25 to € 9.35, based on an underlying tax rate of 22 %. Overview of the key figures for Q2 2023 Group Key figures € million Q2 2023 Q2 2022 Change Jan.-June 2023 Jan.-June 2022 Change Net sales 5,302 5,568 -4.8% 10,595 10,766 -1.6% Operating result (EBIT) 1 969 1,177 -17.6% 2,004 2,350 -14.7% Margin (% of net sales) 1 18.3% 21.1% 18.9% 21.8% EBITDA 2 1,452 1,709 -15.1% 2,942 3,312 -11.2% Margin (% of net sales) 1 27.4% 30.7% 27.8% 30.8% EBITDA pre 1 1,553 1,782 -12.8% 3,140 3,411 -7.9% Margin (% of net sales) 1 29.3% 32.0% 29.6% 31.7% Profit after tax 706 870 -18.9% 1,506 1,754 -14.1% Earnings per share (€) 1.62 1.99 -18.6% 3.45 4.02 -14.2% Earnings per share pre (€) 1 2.20 2.64 -16.7% 4.57 5.05 -9.5% Operating cash flow 622 852 -27.0% 1,475 1,692 -12.8% Net financial debt 3 9,355 8,328 12.3% – – - Number of employees 4 63,701 62,759 1.5% – – - 1 Not defined by International Financial Reporting Standards (IFRS). 2 Not defined by International Financial Reporting Standards (IFRS); EBITDA corresponds to operating result (EBIT) adjusted by depreciation, amortization, impairment losses, and reversals of impairment losses. 3 Figures for the reporting period ending on June 30, 2023, prior-year figures as of December 31, 2022. 4 Figures for the reporting period ending on June 30, 2023, prior-year figures as of June 30, 2022. Prior-year figures have been adjusted. This figure refers to all employees at sites of fully consolidated entities. Life Science Net sales by business unit € million Q2 2023 Share Organic growth 1 Exchange rate effects Acquisitions/ divestments Total change Q2 2022 2 Share Science & Lab Solutions 1,182 50% -1.1% -2.9% – -4.1% 1,232 46% Process Solutions 994 42% -11.8% -2.1% – -13.9% 1,154 44% Life Science Services 178 8% -30.5% -1.4% – -31.9% 262 10% Life Science 2,354 100% -8.7% -2.4% – -11.1% 2,648 100% 1 Not defined by International Financial Reporting Standards (IFRS). 2 Prior-year figures have been adjusted owing to an internal realignment. Healthcare Net sales by major product lines/products € million Q2 2023 Share Organic growth 1 Exchange rate effects Total change Q2 2022 Share Oncology 458 22% 17.8% -7.7% 10.1% 415 22% thereof: Erbitux ® 260 13% 10.2% -9.2% 1.1% 258 13% thereof: Bavencio ® 178 9% 26.8% -5.0% 21.8% 146 8% Neurology & Immunology 467 23% 12.2% -3.4% 8.8% 429 22% thereof: Rebif ® 205 10% -3.2% -2.4% -5.6% 217 11% thereof: Mavenclad ® 262 13% 28.1% -4.5% 23.6% 212 11% Fertility 409 20% 24.7% -8.1% 16.5% 351 18% thereof: Gonal-f ® 219 11% 18.7% -8.6% 10.1% 198 10% Cardiovascular, Metabolism and Endocrinology 665 32% 0.9% -4.6% -3.7% 690 36% thereof: Glucophage ® 197 10% -8.9% -4.6% -13.6% 228 12% thereof: Concor ® 142 7% 1.8% -5.7% -3.9% 147 8% thereof: Euthyrox ® 131 6% -2.3% -3.4% -5.8% 139 7% thereof: Saizen ® 79 4% 22.1% -5.9% 16.2% 68 4% Other 50 3% 38 2% Healthcare 2,049 100% 11.9% -5.4% 6.5% 1,924 100% 1 Not defined by International Financial Reporting Standards (IFRS). Electronics Net sales by business unit € million Q2 2023 Share Organic growth 1 Exchange rate effects Acquisitions/ divestments Total change Q2 2022 Share Semiconductor Solutions 602 67% -4.7% -3.6% 0.5% -7.8% 653 66% Display Solutions 196 22% -10.9% -4.9% – -15.8% 233 23% Surface Solutions 101 11% -5.8% -2.8% – -8.7% 111 11% Electronics 899 100% -6.3% -3.8% 0.3% -9.7% 996 100% 1 Not defined by International Financial Reporting Standards (IFRS). Notes to editors: The press conference for media representatives will take place at 9:30 a.m. (CEST). The respective presentation and further information for journalists, including a digital press kit , can be found here The half-yearly financial report can be found here Twitter and LinkedIn Photos and images can be found here Stock symbols Reuters: MRCG, Bloomberg : MRK GY, Dow Jones : MRK.DE Frankfurt Stock Exchange : ISIN : DE 000 659 9905 – WKN : 659 990 All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group website. In case you are a resident of the USA or Canada, please go to www.emdgroup.com/subscribe to register for your online, change your selection or discontinue this service. About Merck KGaA, Darmstadt, Germany Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 64,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022, Merck KGaA, Darmstadt, Germany, generated sales of € 22.2 billion in 66 countries. The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company

Financial results of Q1 2023 Group net sales rise by 1.8% to € 5.3 billion New Healthcare products major growth drivers EBITDA pre down −2.6% to € 1.6 billion Medium-term structural growth drivers intact Forecast for fiscal 2023 Net sales: organic growth of 1% to 4% Net sales excluding Covid-19-related business: organic increase of 4% to 7% EBITDA pre: organic decline of −5% to stable at 0% Negative foreign exchange effects on net sales and EBITDA pre of − 5% to − 2% expected Darmstadt, Germany, May 11, 2023 – Merck KGaA, Darmstadt, Germany, a leading science and technology company, generated net sales of € 5.3 billion in the first quarter of 2023. This corresponds to an increase of 1.8% over the year-earlier quarter (organically 0.8%). Sales growth was in particular attributable to Healthcare, which delivered significant increases in its business with new medicines, one of the company’s “Big 3” growth drivers. Life Science, in particular the Science & Lab Solutions business unit, also contributed positively to sales growth. EBITDA pre decreased by −2.6% (organically −1.7%) to € 1.6 billion. The main reasons for this were the decline in the Display Solutions business as well as the significant decrease in earnings contributions from Covid-19-related sales. “2023 will be a transition year for us. As expected, our Life Science and Electronics businesses were confronted with a difficult market environment in the first quarter. The weaker market for Display and Semiconductor Solutions as well as the continued decline in Covid-19-related sales weighed on our business performance,” said Belén Garijo, Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany. “At the same time, Healthcare benefited from the growth of new products. This proves the resilience of our diversified, multi-industry portfolio. Our structural growth drivers remain intact. We are confident that we will be able to achieve our medium-term target of 25 billion euros in sales by 2025.” In the first quarter of 2023, the company continued to drive key growth and strategic initiatives. A team from the Life Science business sector helped to further drive digitalization by publishing its code library together with partner Palantir in March. It is the first-ever customer-developed, open-source library for Palantir Foundry that provides consistent digital blueprints to boost productivity and quality for developers. In March, the Group strengthened its Oncology franchise and terminated the alliance agreement with Pfizer on Bavencio. Effective June 30, 2023, the company will regain the exclusive worldwide rights to develop, manufacture and commercialize Bavencio. As a result, Merck KGaA, Darmstadt, Germany, expects a significant increase in profit from sales of Bavencio. In the Electronics business sector, construction work for a new production facility for semiconductor materials began in Kaohsiung, Taiwan, in February. Lower customer utilization in Display Solutions and continued decline in Covid-19-related demand impact earnings Group net sales rose organically by 0.8% to € 5,293 million in the first quarter of 2023. Foreign exchange effects, especially from the development of the U.S. dollar, contributed 0.8% to the growth in sales. Portfolio effects were responsible for 0.2% and were mainly attributable to the acquisitions of the biopharmaceutical contract development and manufacturing organization Exelead, Inc., USA, as well as the chemical business of Mecaro Co. Ltd., a Korea-based supplier to the semiconductor industry. EBITDA pre fell by −2.6% to € 1,587 million. Organically, the decline amounted to −1.7%. Among other things, this was due to lower customer utilization in Display Solutions as well as the significant decrease in earnings contributions from Covid-19-related sales. In addition, one-time effects such as royalty and license income had a positive impact on EBITDA pre in the year-earlier quarter. EBITDA pre was adversely affected by foreign exchange effects of −0.5% and a portfolio impact of −0.4%. The EBITDA pre margin was 30.0% and EPS pre amounted to € 2.36. Life Science: Robust growth in core business compensates decline in Covid-19-related demand In the first quarter of 2023, the Life Science business sector generated net sales of € 2,487 million. The robust growth in the core business compensated for the expected, sharp decline in Covid-19-related sales. Compared with the year-earlier quarter, this represents an increase of 1.7%, comprising 0.6% from organic growth, 0.9% from foreign exchange effects and 0.3% from acquisitions. The Process Solutions (−4.1%) and Life Science Services (−7.2%) business units saw organic sales declines due to the significant decrease in Covid-19-related demand. By contrast, the net sales of Science & Lab Solutions increased organically by 5.9%. This business unit offers products and services to support research activities. With net sales of € 1,276 million, it accounted for 51% of Life Science sales in the first quarter. EBITDA pre of Life Science decreased by −2.9% to € 901 million compared with the first quarter of 2022. This reflected the lower share of Covid-19-related sales and earnings as well as higher investments in growth segments such as novel modalities, among other things. Organically, the decline amounted to −1.4%. Foreign exchange was responsible for −1.0%, and portfolio effects for −0.5%. The EBITDA pre margin of Life Science was 36.2%. Healthcare: Very good first quarter driven by growth of recent launches In the first quarter of 2023, sales of the Healthcare business sector increased by 6.2% to € 1,905 million. Organic growth was 5.3%. Foreign exchange had a positive effect of 0.8% on sales growth. The key growth drivers were once again new Healthcare products: The immuno-oncology drug Bavencio generated an organic sales increase of 30.6%. Sales of Mavenclad for the treatment of relapsing multiple sclerosis grew organically by 23.0%. Both the Fertility and the Cardiovascular, Metabolism & Endocrinology franchises saw organic sales growth of their portfolio products. EBITDA pre of Healthcare rose by 11.4% to € 590 million in the first quarter of 2023. Organic growth was 10.5%, supported by positive foreign exchange effects of 0.9%. The EBITDA pre margin of the business sector came in at 30.9%. Electronics: Semiconductor Solutions grows slightly despite decline in the semiconductor materials market; continued weakness of Liquid Crystals In the Electronics business sector, sales decreased by −5.9% to € 901 million in the first quarter of 2023. The organic decline of −7.1% was mitigated by positive foreign exchange effects of 0.8% as well as a portfolio effect of 0.3%. In a semiconductor market that slowed as expected, Semiconductor Solutions generated an organic sales increase of 2.0%, well above market. This business unit accounted for around two thirds of the sales of Electronics. By contrast, the Display Solutions (−28.1%) and Surface Solutions (−4.9%) business units saw organic sales declines. In Display Solutions, this was due in particular to continued low demand for liquid crystals. EBITDA pre of Electronics decreased by −18.0% to € 237 million compared with the year-earlier quarter. The organic decline amounted to −19.8%. The further price decline in the Liquid Crystals business, the weaker market environment in Semiconductor Solutions as well as cost inflation had negative impacts. Foreign exchange effects of 2.3% made a positive contribution to the development of EBITDA pre, whereas the acquisition of the chemical business of Mecaro had a negative impact of −0.4 % on this figure. The EBITDA pre margin of Electronics was 26.4%. Forecast for fiscal 2023: Healthcare remains a growth driver; negative impacts from softer market environment in Electronics, continued decline of Covid-19-related demand and high cost level The Group is specifying the forecast for fiscal 2023. For sales, the company expects growth especially from new Healthcare products and the Life Science core business. Negative impacts are likely from declining Covid-19-related sales, the slowing Display Solutions business and an even more pronounced weakening of the semiconductor materials market. This market is expected to recover in the second half of 2023, but at a later point and from a lower base than previously assumed. For EBITDA pre, the company expects the high level of costs due to inflation to weigh on earnings of all business sectors, in particular in Life Science and Electronics. EBITDA pre of Healthcare is forecast to increase organically, mainly thanks to the expected strong business performance. In summary, the Group expects for fiscal 2023: Net sales of between € 21.2 billion and € 22.7 billion (2022: € 22.2 billion) Thereof: organic growth of 1% to 4% Excluding Covid-19-related sales: organic sales growth of 4% to 7% Sales from Covid-19-related demand: around € 250 million Negative foreign exchange effects of −5% to −2% EBITDA pre of € 6.1 billion to € 6.7 billion (2022: € 6.8 billion) Organic decline of −5% to stable at 0% Negative foreign exchange effects of −5% to −2% EPS pre of € 8.80 to € 9.90, based on an underlying tax rate of 22% Overview of the key figures for Q1 2023 Group Key figures € million Q1 2023 Q1 2022 Change Net sales 5,293 5,198 1.8% Operating result (EBIT) 1 1,035 1,173 -11.8% Margin (% of net sales) 1 19.6% 22.6% EBITDA 2 1,491 1,603 -7.0% Margin (% of net sales) 1 28.2% 30.8% EBITDA pre 1 1,587 1,629 -2.6% Margin (% of net sales) 1 30.0% 31.3% Profit after tax 800 884 -9.5% Earnings per share (in €) 1.83 2.02 -9.4% Earnings per share pre (€) 1 2.36 2.41 -2.1% Operating cash flow 853 840 1.5% Net financial debt 3 8,992 8,328 8.0% Number of employees 4 64,011 61,517 4.1% 1 Not defined by International Financial Reporting Standards (IFRS). 2 Not defined by International Financial Reporting Standards (IFRS); EBITDA corresponds to operating result (EBIT) adjusted by depreciation, amortization, impairment losses, and reversals of impairment losses. 3 Figures for the reporting period ending on March 31, 2023, prior-year figures as of December 31, 2022. 4 Figures for the reporting period ending on March 31, 2023, prior-year figures as of March 31, 2022. Prior-year figures have been adjusted. This figure refers to all employees at sites of fully consolidated entities. Life Science Net sales by business unit € million Q1 2023 Share Organic growth 1 Exchange rate effects Acquisitions/ divestments Total change Q1 2022 2 Share Science & Lab Solutions 1,276 51% 5.9% 0.5% – 6.5% 1,199 49% Process Solutions 1,022 41% -4.1% 1.1% 0.1% -3.0% 1,053 43% Life Science Services 188 8% -7.2% 1.7% 2.9% -2.6% 193 8% Life Science 2,487 100% 0.6% 0.9% 0.3% 1.7% 2,445 100% 1 Not defined by International Financial Reporting Standards (IFRS). 2 Previous year’s figures have been adjusted owing to an internal realignment. Healthcare Net sales by major product lines/products € million Q1 2023 Share Organic growth 1 Exchange rate effects Total change Q1 2022 Share Oncology 433 23% 14.7% -0.4% 14.3% 379 21% thereof: Erbitux ® 250 13% 3.7% -0.6% 3.1% 242 13% thereof: Bavencio ® 167 9% 30.6% – 30.7% 128 7% Neurology & Immunology 390 20% -2.0% 1.9% -0.1% 391 22% thereof: Rebif ® 154 8% -25.4% 1.6% -23.8% 201 11% thereof: Mavenclad ® 237 12% 23.0% 2.2% 25.2% 189 11% Fertility 366 19% 6.7% 0.6% 7.3% 341 19% thereof: Gonal-f ® 197 10% -2.1% 0.7% -1.4% 200 11% Cardiovascular, Metabolism and Endocrinology (CM&E) 677 36% 3.0% 0.8% 3.8% 652 36% thereof: Glucophage ® 218 11% -0.1% 0.2% 0.1% 218 12% thereof: Concor ® 142 7% 0.8% 2.0% 2.9% 138 8% thereof: Euthyrox ® 130 7% 0.4% 0.5% 0.9% 128 7% thereof: Saizen ® 76 4% 25.1% -0.1% 25.0% 61 3% Other 38 2% 32 2% Healthcare 1,905 100% 5.3% 0.8% 6.2% 1,795 100% 1 Not defined by International Financial Reporting Standards (IFRS). Electronics Net sales by business unit € million Q1 2023 Share Organic growth 1 Exchange rate effects Acquisitions/ divestments Total change Q1 2022 Share Semiconductor Solutions 604 67% 2.0% 1.6% 0.5% 4.1% 581 61% Display Solutions 187 21% -28.1% -0.4% – -28.5% 262 27% Surface Solutions 109 12% -4.9% -0.2% – -5.1% 115 12% Electronics 901 100% -7.1% 0.8% 0.3% -5.9% 957 100% 1 Not defined by International Financial Reporting Standards (IFRS). Notes to editors: The press conference for media representatives will take place at 9:30 a.m. (CEST). The respective presentation and further information for journalists, including a digital press kit , can be found here The quarterly statement can be found here Twitter and LinkedIn Photos and images can be found here Stock symbols Reuters: MRCG, Bloomberg : MRK GY, Dow Jones : MRK.DE Frankfurt Stock Exchange : ISIN : DE 000 659 9905 – WKN : 659 990 All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group website. In case you are a resident of the USA or Canada, please go to www.emdgroup.com/subscribe to register for your online, change your selection or discontinue this service. About Merck KGaA, Darmstadt, Germany Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 64,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022, Merck KGaA, Darmstadt, Germany, generated sales of € 22.2 billion in 66 countries. The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.